MGI Pharma has announced plans to launch late-stage trials of the experimental surgical sedative Aquavan in the early part of 2006. MGI also announced that clinical trial data indicates that the higher dose of the drug appears to be most effective. MGI acquired Aquavan when it bought Guilford Pharmaceuticals in October.
"Aquavan Injection for minimal to moderate procedural sedation represents an excellent market opportunity for MGI Pharma, as we continue to strengthen our acute care portfolio and advance our pipeline of late stage product candidates," said Lonnie Moulder, president and CEO of MGI. "We look forward to initiating a pivotal program for this product candidate in early 2006."
- read this AP report for more information